Expression of Cyclooxygenase-2 in Normal Urothelium, and Superficial and Advanced Transitional Cell Carcinoma of Bladder

Journal of Urology

Volumn 177, Issue 3, 2007, Pages 1163-1168

  Margulis, Vitaly ^a   Shariat, Shahrokh F ^a   Ashfaq, Raheela ^a   Thompson, Melissa ^a   Sagalowsky, Arthur I ^a   Hsieh, Jer Tsong ^a   Lotan, Yair ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

bladder; bladder neoplasms; carcinoma; cyclooxygenase 2; mortality; transitional cell

Indexed keywords

CASPASE 3; CYCLIN D1; CYCLIN E; CYCLOOXYGENASE 2; KI 67 ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN; SURVIVIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; BLADDER METASTASIS; CANCER INVASION; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; CYSTECTOMY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPH VESSEL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT CANCER; STAINING; SUPERFICIAL CANCER; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; UNIVARIATE ANALYSIS; UROTHELIUM;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, TRANSITIONAL CELL; CASE-CONTROL STUDIES; CELL CYCLE PROTEINS; COHORT STUDIES; CYCLOOXYGENASE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 33846807872     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.10.033     Document Type: Article

References (20)

1. Cao Y., and Prescott S.M. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 190 (2002) 279
2. Mohammed S.I., Knapp D.W., Bostwick D.G., Foster R.S., Khan K.N., Masferrer J.L., et al. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res 59 (1999) 5647
3. Shirahama T., Arima J., Akiba S., and Sakakura C. Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer 92 (2001) 188
4. Mohammed S.I., Bennett P.F., Craig B.A., Glickman N.W., Mutsaers A.J., Snyder P.W., et al. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res 62 (2002) 356
5. Grubbs C.J., Lubet R.A., Koki A.T., Leahy K.M., Masferrer J.L., Steele V.E., et al. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fisher-344 rats. Cancer Res 60 (2000) 5599
6. Mohseni H., Zaslau S., McFadden D., Riggs D.R., Jackson B.J., and Kandzari S. COX-2 inhibition demonstrates potent anti-proliferative effects on bladder cancer in vitro. J Surg Res 119 (2004) 138
7. Castelao J.E., Yuan J.M., Gago-Dominguez M., Yu M.C., and Ross R.K. Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer 82 (2000) 1364
8. Divi R.L., Dragan Y.P., Pitot H.C., and Poirier M.C. Immunohistochemical localization and semi-quantitation of hepatic tamoxifen-DNA adducts in rats exposed orally to tamoxifen. Carcinogenesis 22 (2001) 1693
9. Wang S., Saboorian M.H., Frenkel E.P., Haley B.B., Siddiqui M.T., Gokaslan S., et al. Assessment of HER-2/neu status in breast cancer. Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. Am J Clin Pathol 116 (2001) 495
10. Lotan Y., Gupta A., Shariat S., Palapattu G., Vazina A., Karakiewicz P., et al. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol 23 (2005) 6533
11. Pereg D., and Lishner M. Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer. J Intern Med 258 (2005) 115
12. Shariat S.F., Matsumoto K., Kim J., Ayala G.E., Zhou J.H., Jian W., et al. Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder. J Urol 170 (2003) 985
13. Li G., Yang T., Li L., Yan J., Zeng Y., Yu J., et al. Cyclooxygenase-2 parallels invasive depth and increased MVD in transitional cell carcinoma. Colloids Surf B Biointerfaces 37 (2004) 15
14. Kim S.I., Kwon S.M., Kim Y.S., and Hong S.J. Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancer. Urology 60 (2002) 816
15. Pruthi R.S., Derksen E., Gaston K., and Wallen E.M. Rationale for use of cyclooxygenase-2 inhibitors in prevention and treatment of bladder cancer. Urology 64 (2004) 637
16. Narayanan B.A., Condon M.S., Bosland M.C., Narayanan N.K., and Reddy B.S. Suppression of N-methyl-N-nitrosourea/testosterone-induced rat prostate cancer growth by celecoxib: effects on cyclooxygenase-2, cell cycle regulation, and apoptosis mechanism(s). Clin Cancer Res 9 (2003) 3503
17. Cheng J., Imanishi H., Amuro Y., and Hada T. NS-398, a selective cyclooxygenase 2 inhibitor, inhibited cell growth and induced cell cycle arrest in human hepatocellular carcinoma cell lines. Int J Cancer 99 (2002) 755
18. Grosch S., Tegeder I., Niederberger E., Brautigam L., and Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 15 (2001) 2742
19. Diamantopoulou K., Lazaris A., Mylona E., Zervas A., Stravodimos K., Nikolaou I., et al. Cyclooxygenase-2 protein expression in relation to apoptotic potential and its prognostic significance in bladder urothelial carcinoma. Anticancer Res 25 (2005) 4543
20. McGinty A., Chang Y.W., Sorokin A., Bokemeyer D., and Dunn M.J. Cyclooxygenase-2 expression inhibits trophic withdrawal apoptosis in nerve growth factor-differentiated PC12 cells. J Biol Chem 275 (2000) 12095